Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation

Ocular Infections, Irritations and Inflammations Clinical Trial

— Hawaii-1  

Official title:

A Phase III, Double-Masked, Randomized, Controlled Trial of KPI-121 in Postsurgical Inflammation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02163824
• Other study ID #: KPI-121-C-001
• Status: Completed
• Phase: Phase 3
• Start date: May 2014
• Est. completion date: December 2014

Study information

• Verified date: January 2021
• Source: Kala Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery. The efficacy and safety of two different concentrations and two different dosing regimens of KPI-121 are also being assessed.

Description:

This is a Phase III, multicenter, double-masked, randomized, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of two doses and two dosing regimens of KPI-121 ophthalmic suspension versus placebo in subjects who require treatment of postoperative anterior ocular inflammation.

Approximately 500 subjects will be screened and up to 402 subjects with one study eye each will be randomized in this study at approximately 25 centers located in the United States. Subjects who experience postoperative inflammation on the first day following routine, uncomplicated, cataract surgery and who meet all other eligibility criteria will be randomized to one of four study groups (0.25% four times daily or 1.0% two times daily) or Placebo A four times daily or Placebo B two times daily. Drug product or placebo will be initiated on the day following surgery and instilled as one to two drops in the study eye according to the assigned dosing regimen for 14 days.

This study will include up to 7 clinic visits (including the surgery day) over 18 to 33 days total study duration. Visit 1 (Screening) will occur between 14 to 1 day(s) prior to surgery, and subjects who meet preoperative screening inclusion/exclusion criteria will be entered into the study. At Visit 2 (Surgery/Day 0) subjects will undergo routine cataract surgery according to the Investigator's normal procedures. Visit 3 (Randomization/Day 1) will occur on the day following surgery.

Following randomization, subjects will be instructed to return to the clinic to be evaluated at Visit 4 (Day 3 +2 day), Visit 5 (Day 8 ±1 day), and Visit 6 (Day 15 ±1 day). The last dose of study product will be administered upon completion of 14 days of evaluation. Following the End of Study Product Use Visit (Visit 6; Day 15 ±1 day), subjects will be asked to return to the clinic on Day 17-19 for Visit 7 (Follow-Up) and will be released from the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 380
• Est. completion date: December 2014
• Est. primary completion date: December 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

FURTHER STUDY DETAILS PROVIDED BY KALA PHARMACEUTICALS, INC.

Inclusion Criteria:

• Candidates for routine, uncomplicated cataract surgery

• In Investigator's opinion, potential postoperative Snellen Distance VA by pinhole method of at least 20/200 in study eye.

Exclusion Criteria:

• Known hypersensitivity/contraindication to study product(s) or components.

• History of glaucoma, IOP >21 mmHg at the screening or randomization visits, or being treated for glaucoma in either eye.

• Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in judgment of Investigator could confound study assessments or limit compliance; severe/serious systemic disease or uncontrolled medical condition that in judgment of Investigator could confound study assessments or limit compliance; or have been exposed to an investigational drug within the 30 days prior to screening or 19 days following surgery.

• In the opinion of Investigator or study coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops.

Related Conditions & MeSH terms

• Eye Infections
• Inflammation
• Ocular Infections, Irritations and Inflammations

Intervention

Drug:
• KPI-121 0.25%
KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
• KPI-121 1.0%
KPI-121 drug product will be supplied as 1.0% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
• Vehicle of KPI-121 0.25%
Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
• Vehicle of KPI-121 1.0%
Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.

Locations

Country	Name	City	State
United States	Sall Research Medical Center	Artesia	California
United States	Cincinnati Eye Institute	Cincinnati	Ohio
United States	The Eye Center of Columbus	Columbus	Ohio
United States	Las Vegas Physicians Research Group	Henderson	Nevada
United States	Cornerstone Eye Care	High Point	North Carolina
United States	Price Vision Group	Indianapolis	Indiana
United States	Tauber Eye Center	Kansas City	Missouri
United States	The Eye Clinic of Texas, Affiliate of Houston Eye Associates	League City	Texas
United States	Taustine Eye Center	Louisville	Kentucky
United States	North Valley Eye Medical Group	Mission Hills	California
United States	Clayton Eye Center	Morrow	Georgia
United States	John-Kenyon American Eye Institute	New Albany	Indiana
United States	Raymond Fong, MDPC	New York	New York
United States	Virginia Eye Consultants	Norfolk	Virginia
United States	Martel Eye Medical Group	Rancho Cordova	California
United States	Rochester Ophthalmological Group, PC	Rochester	New York
United States	Ophthalmology Associates	Saint Louis	Missouri
United States	Ophthalmology Consultants	Saint Louis	Missouri
United States	Tekwani Vision Center	Saint Louis	Missouri
United States	Kozlovsky Delay & Winter Eye Consultants, LLC	San Antonio	Texas
United States	R&R Eye Research, LLC	San Antonio	Texas
United States	Westside Research, LLC	Spartanburg	South Carolina
United States	Wolstan & Goldberg Eye Associates	Torrance	California

Sponsors (1)

Lead Sponsor	Collaborator
Kala Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Resolution of Anterior Chamber Cells	Subjects with complete resolution of anterior chamber cells (cell score = 0) without rescue medication at Day 8/Visit 5 and Day 15/Visit 6.; 0= No cells seen; 1 to 5 cells; 6 to 15 cells; 16 to 30 cells; greater than 30 cells	Visit 5 (postoperative day 8) and Visit 6 (postoperative day 15)
Primary	Resolution of Ocular Pain	Subjects with complete resolution of pain (grade = 0) without rescue medication at Day 8/Visit 5 and Day 15/Visit 6.	Visit 5 (postoperative day 8) and Visit 6 (postoperative day 15)
Secondary	Anterior Chamber Cell Grade at Visit 5.	Mean Grade of Anterior Chamber Cells (Scale 0-4) at Visit 5/Day 8. The difference in mean grade of AC cell count grade at Day 8 for KPI-121 1% dosed twice daily (BID) or 0.25% dosed four times daily (QID) compared with vehicle (either dosed BID or QID). Investigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better.; Anterior Chamber Cells 0 = No cells seen; 1 - 5 cells; 6 - 15 cells; 16 - 30 cells 4 = greater than 30 cells	Visit 5 (postoperative day 8)
Secondary	Anterior Chamber Cell Grade at Visit 6.	Mean Grade of Anterior Chamber Cells (Scale 0-4) at Visit 6/Day 15. The difference in mean grade of AC cell count grade at Day 15 for KPI-121 1% dosed twice daily (BID) or 0.25% dosed four times daily (QID) compared with vehicle (either dosed BID or QID). Investigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better.; Anterior Chamber Cells 0 = No cells seen; 1 - 5 cells; 6 - 15 cells; 16 - 30 cells 4 = greater than 30 cells	Visit 6 (postoperative day 15)
Secondary	Ocular Pain Grades at Day 8.	Mean Grade of Ocular Pain (Scale 0-5) at Visit 5/Day 8. The difference in mean grade of ocular pain grade at Day 8 for KPI-121 1% dosed twice daily (BID) or 0.25% dosed four times daily (QID) compared with vehicle (either dosed BID or QID). Subjects were given the Subject-Rated Ocular Pain Assessment to subjectively rate their pain. Higher scores were worse outcomes.; The following scoring scale was used for ocular pain: 0 = None; Minimal; Mild; Moderate; Moderately Severe; Severe	Visit 5 (postoperative day 8)
Secondary	Ocular Pain Grades at Day 15.	Mean Grade of Ocular Pain (Scale 0-5) at Visit 6/Day 15. The difference in mean grade of ocular pain grade at Day 15 for KPI-121 1% dosed twice daily (BID) or 0.25% dosed four times daily (QID) compared with vehicle (either dosed BID or QID). Subjects were given the Subject-Rated Ocular Pain Assessment to subjectively rate their pain.; Higher scores were worse outcomes.; The following scoring scale was used for ocular pain: 0 = None; Minimal; Mild; Moderate; Moderately Severe; Severe	Visit 6 (postoperative day 15)